Lina van der Straten

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 11

Top Topics

Chronic Lymphocytic Leukemia

Prognostic Factors

Ejection Fraction

Top Venues

Blood cancer journal

Leukemia & lymphoma

British journal of haematology

Annals of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Lina van der Straten, Mark-David Levin, Manette A W Dinnessen, Otto Visser, Eduardus F M Posthuma, Jeanette K Doorduijn, Anton W Langerak, Arnon P Kater, Avinash G Dinmohamed
Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019. Blood cancer journal 13 (1) (2023)
Lina van der Straten, Mark-David Levin, Manette A W Dinnessen, Otto Visser, Eduardus F M Posthuma, Jeanette K Doorduijn, Anton W Langerak, Arnon P Kater, Avinash G Dinmohamed
Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019. Blood cancer journal 13 (1) (2023)
Lina van der Straten, Mark-David Levin, Manette A W Dinnessen, Otto Visser, Eduardus F M Posthuma, Jeanette K Doorduijn, Anton W Langerak, Arnon P Kater, Avinash G Dinmohamed
Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019. Blood cancer journal 13 (1) (2023)
Lina van der Straten, Mark-David Levin, Manette A W Dinnessen, Otto Visser, Eduardus F M Posthuma, Jeanette K Doorduijn, Anton W Langerak, Arnon P Kater, Avinash G Dinmohamed
Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019. Blood cancer journal 13 (1) (2023)
Lina van der Straten, Carolien C H M Maas, Mark-David Levin, Otto Visser, Eduardus F M Posthuma, Jeanette K Doorduijn, Anton W Langerak, Arnon P Kater, Avinash G Dinmohamed
Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2018. Blood cancer journal 12 (4) (2022)
Doreen G Te Raa, Lina van der Straten, Michel van Gelder, Sabina Kersting, Mark-David Levin, Rogier Mous, Hanneke M van der Straaten, Marten R Nijziel, Ellen van der Spek, Eduardus F M Posthuma, Hein P J Visser, Marjolein van der Klift, Koen de Heer, Mar Bellido, Jeanette K Doorduijn, Anke H W Bruns, Reinier A P Raijmakers, Arnon P Kater, null null
Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. Leukemia & lymphoma 63 (10) (2022)
Lina van der Straten, Mark-David Levin, Otto Visser, Eduardus F M Posthuma, Jeanette K Doorduijn, Arnon P Kater, Avinash G Dinmohamed
Conditional relative survival among patients with chronic lymphocytic leukaemia: A population-based study in the Netherlands. EJHaem 3 (1) (2021)
Lina van der Straten, Mark-David Levin, Otto Visser, Eduardus F M Posthuma, Jeanette K Doorduijn, Arnon P Kater, Avinash G Dinmohamed
Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016. British journal of haematology 189 (3) (2020)
Lina van der Straten, Mark-David Levin, Otto Visser, Nicole M A Blijlevens, Jan J Cornelissen, Jeanette K Doorduijn, Arnon P Kater, Avinash G Dinmohamed
The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands. British journal of haematology 188 (6) (2020)
Lina van der Straten, Arnon P Kater, Jeanette K Doorduijn, Esther C van den Broek, Eduardus F M Posthuma, Avinash G Dinmohamed, Mark-David Levin
Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia. Annals of hematology 99 (5) (2020)
Lina van der Straten, Avinash G Dinmohamed, Peter E Westerweel, Anton W Langerak, Jurgen Riedl, Jeanette K Doorduijn, Arnon P Kater, Mark-David Levin
Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy. Leukemia & lymphoma 59 (11) (2018)